Skip to main content
SpringerLink
Log in

Non-steroidal anti-inflammatory drugs

  • Chapter
Clinical Nephrotoxins

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennet WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(Suppl 1): 56–62.

    Google Scholar 

  2. Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insights. J Nephrol 1998; 11: 70–75.

    CAS  PubMed  Google Scholar 

  3. Whelton A. Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: Primer On Kidney Diseases. Greenberg A (editor). Academic Press, San Diego 1994; 163–167.

    Google Scholar 

  4. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 1999; 106: 13S–24S.

    Article  CAS  PubMed  Google Scholar 

  5. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999; 107: 65S–71S.

    Article  CAS  PubMed  Google Scholar 

  6. Personal communication, Evans T, McNeil Consumer Health Care, 2000.

    Google Scholar 

  7. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588–598.

    CAS  PubMed  Google Scholar 

  8. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12.

    CAS  PubMed  Google Scholar 

  9. Breyer MD, Harris RC. Cyclooxgenase-2 and the kidney. Curr Opin Nephrol Hypertens 2001; 10: 89–98.

    CAS  PubMed  Google Scholar 

  10. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ II. Clinical implications of prostaglandin and thromboxane A2 formation (2 parts). N Engl J Med 1988; 319: 689–69 and 761–767.

    CAS  PubMed  Google Scholar 

  11. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 6: 433–442.

    Google Scholar 

  12. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563–572.

    CAS  PubMed  Google Scholar 

  13. Stokes JB. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle: selective inhibition of the medullary portion. J Clin Invest 1979; 64: 495–502.

    CAS  PubMed  Google Scholar 

  14. Breyer MD, Zhang YH, Guan YF, Hao CM, Herbert RL, Breyer RM. Regulation of renal function by prostaglandin E receptors. Kidney Int 1998; 54: S88–S94.

    Article  Google Scholar 

  15. O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci 1992; 89: 4888–4892.

    CAS  PubMed  Google Scholar 

  16. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24(Suppl 49): 15–19.

    Google Scholar 

  17. Hla T, Nielson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 1992; 89: 7384–7386.

    CAS  PubMed  Google Scholar 

  18. Kömhoff M, Gröne HJ, Klein T, Seyberth HW, Nusing R. Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272(4 Pt 2): F460–468.

    PubMed  Google Scholar 

  19. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase 2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–2510.

    CAS  PubMed  Google Scholar 

  20. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110(3 Suppl 1): 33–42.

    Google Scholar 

  21. Blume C, Heise G, Muhlfeld A, Bach D, Schrork K, Gerhardz CD, Grabensee B, Heering P. Effect of flosulide, a selective cyclooxygenase inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56: 1770–1778.

    Article  CAS  PubMed  Google Scholar 

  22. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis S. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465–1470.

    Article  CAS  PubMed  Google Scholar 

  23. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1994; 90: 11693–11697.

    Google Scholar 

  24. McMurray RW, Hardy KJ: COX-2 inhibitors: Today and tomorrow. Am J Med Sci. 2002; 323: 181–189.

    PubMed  Google Scholar 

  25. Harris RC. Cyclooxygenase — 2 in the kidney. J Am Soc Nephrol 2000; 11: 2387–2394.

    CAS  PubMed  Google Scholar 

  26. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12.

    CAS  PubMed  Google Scholar 

  27. Stokes JB, Kokko JP. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977; 59: 1099–1104.

    CAS  PubMed  Google Scholar 

  28. Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588–598.

    CAS  PubMed  Google Scholar 

  29. Schlondorf D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643–653.

    Google Scholar 

  30. Murray MD, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci 1990; 229: 222–229.

    Google Scholar 

  31. Whelton A. Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63–74.

    CAS  PubMed  Google Scholar 

  32. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–741.

    CAS  PubMed  Google Scholar 

  33. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109–1120.

    PubMed  Google Scholar 

  34. Ormrod D, Wellington K, Wagstaff AJ: Valdecoxib. Drugs 2002; 62: 2059–2071.

    Article  CAS  PubMed  Google Scholar 

  35. Sedor JR, Williams SL, Chremos AN, Johnson CL, Dunn MJ. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clin Pharmacol Ther 1984; 36: 85–91.

    CAS  PubMed  Google Scholar 

  36. Berg KJ. Acute effects of acetylsalicylic acid on renal function in normal man. Eur J Clin Pharmacol 1977; 11: 117–123.

    CAS  PubMed  Google Scholar 

  37. Donker AJ, Arisz L, Brentjens JR, van der Hem GK, Hollemans HJ. The effect of indomethacin on kidney function and plasma renin activity in man. Nephron 1976; 17: 288–296.

    CAS  PubMed  Google Scholar 

  38. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 2433–2439.

    Article  CAS  PubMed  Google Scholar 

  39. Evans JMM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, McDevitt DG, MacDonald TM. Non-steroidal drugs anti-inflammatory drugs and hospitalization for acute renal failure. QJMed 1995; 88: 551–557.

    CAS  Google Scholar 

  40. Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488–496.

    CAS  PubMed  Google Scholar 

  41. Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal anti-inflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985; 14: 163–175.

    Article  CAS  PubMed  Google Scholar 

  42. Feldman HI, Kinman JL, Berlin JA, Hennessy S, Kimmel SE, Farrar J, Carson JL, Strom BL. Parenteral ketorolac: the risk of acute renal failure. Ann Intern Med 1997; 126: 193–199.

    CAS  PubMed  Google Scholar 

  43. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48: 895–900.

    CAS  PubMed  Google Scholar 

  44. Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983; 84: 697–703.

    CAS  PubMed  Google Scholar 

  45. Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanisms. Ann Intern Med 1979; 91: 47–49.

    CAS  PubMed  Google Scholar 

  46. Arisz L, Donker AJM, Brentjens JRH, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976; 199: 121–125.

    CAS  PubMed  Google Scholar 

  47. Kleinknecht C, Broyer M, Gubler MC, Palcoux JB. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med 1980; 302: 691.

    CAS  PubMed  Google Scholar 

  48. Kimberley RP, Gill JR Jr, Bowden RE, Keiser HR, Plotz PH. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978; 89: 336–341.

    Google Scholar 

  49. Fong HJ, Cohen AH. Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982; 2: 28–31.

    CAS  PubMed  Google Scholar 

  50. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982; 96: 317–20.

    CAS  PubMed  Google Scholar 

  51. Whelton A, Stout RL, Spilman PS, Klassen DL. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568–576.

    CAS  PubMed  Google Scholar 

  52. Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmacol 1995; 35: 454–463.

    CAS  PubMed  Google Scholar 

  53. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307–314.

    Article  CAS  PubMed  Google Scholar 

  54. Galler M, Folkert VW, Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 1981; 246: 154–155.

    Article  CAS  PubMed  Google Scholar 

  55. Findling JW, Beckstrom D, Rawsthorne L, Kozin F, Itskovitz H. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980; 244: 1127–1128.

    Article  CAS  PubMed  Google Scholar 

  56. Nicholls MG, Espiner EA. Indomethacin-induced azotaemia and hyperkalemia: a case study. N Z Med J 1981; 94: 377–379.

    CAS  PubMed  Google Scholar 

  57. Paladini G, Tonazzi C. Indomethacin-induced hyperkalemia and renal failure in multiple myeloma. Acta Haematol 1982; 68: 256–260.

    CAS  PubMed  Google Scholar 

  58. Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J 1985; 78: 756–757.

    CAS  PubMed  Google Scholar 

  59. Mor R, Pitlik S, Rosenfeld JB. Indomethacin-and moduretic-induced hyperkalemia. Isr J Med Sci 1983; 19: 535–537.

    CAS  PubMed  Google Scholar 

  60. Goldszer RC, Coodley EL, Rosner MJ, Simons WM, Schwartz AB. Hyperkalemia associated with indomethacin. Arch Intern Med 1981; 141: 802–804.

    Article  CAS  PubMed  Google Scholar 

  61. MacCarthy EP, Frost GW, Strokes GS. Indomethacin-induced hyperkalemia. Med J Aust 1979; 1: 550.

    CAS  PubMed  Google Scholar 

  62. Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med 1979; 90: 783–785.

    CAS  PubMed  Google Scholar 

  63. Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159–175.

    CAS  PubMed  Google Scholar 

  64. Palmer RH, Haig AE, Flavin SK, Iyengar NK. Effects of ibuprofen, nabumetone and celecoxib on blood pressure control in hypertensive patients on ACE inhibitors. Am J Hypertens 2001; 14: 85A.

    Article  Google Scholar 

  65. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hyperten 2002;39:929–934.

    CAS  Google Scholar 

  66. Vioxxâ [package insert]. Whitehouse Station, NJ: Merck & Co, March 2000.

    Google Scholar 

  67. Orloff J, Handler JS, Bergstrom S. Effect of prostaglandin (PGE1) on the permeability response of the toad bladder to vasopressin, theophylline and adenosine 3′, 5′-monophosphate. Nature 1965; 205: 397–398.

    CAS  PubMed  Google Scholar 

  68. Anderson RJ, Berl T, McDonald KM, Schrier RW. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 1975; 56: 420–426.

    CAS  PubMed  Google Scholar 

  69. Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977; 237: 1716–1717.

    Article  CAS  PubMed  Google Scholar 

  70. Blum M, Aviram A. Ibuprofen induced hyponatremia. Rheumatol Rehabil 1980; 19: 258–259.

    CAS  PubMed  Google Scholar 

  71. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of anti-hypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272: 781–786.

    CAS  PubMed  Google Scholar 

  72. Pope JE, Anderson JJ, Felson, DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477–484.

    Article  CAS  PubMed  Google Scholar 

  73. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis [see comments]. Ann Intern Med 1994; 121: 289–300.

    CAS  PubMed  Google Scholar 

  74. Fogari R, Zoppi A, Carretta R Veglio F, Salvetti A: Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicenter study. J Hyperten 2002;20:1007–1014.

    CAS  Google Scholar 

  75. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998; 20: 376–387.

    Article  CAS  PubMed  Google Scholar 

  76. Schwartz JI, Malice MP, Kalyani R, Lasseter K, Holmes GB, Gertz BJ, Gottesdiener K, Laurenzi M, Brune K. Effect of rofecoxib, celecoxib, and naproxen on blood pressure in elderly volunteers. Am J Hypert 2001; 14: 177A.

    Google Scholar 

  77. Celis H, Thijs L, Staessen JA, Birkenhager WH, Bulpitt CJ, deLeeuw PW, Leonetti G, Nachev C, Tuomilehto J, Fagard RH: Interaction between nonsteroidal anti-inflammatory drug intake and calcium channel blocker-based antihypertensive treatment in Syst-Eur trial. J Human Hyperten 2001;15:613–8.

    CAS  Google Scholar 

  78. Raij L, Baylis C. Nitric oxide and the glomerulus. Kidney Int 1995; 48: 20–32.

    CAS  PubMed  Google Scholar 

  79. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Basile Fasolo C, Sudano I, Salvetti A. Aging and endothelial function in the normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981–1987.

    CAS  PubMed  Google Scholar 

  80. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349: 837–842.

    Article  CAS  PubMed  Google Scholar 

  81. Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A: Effect of L-arginine on systemic and renal haemondynamics in salt-sensitive patients with essential hypertension. J Hum Hyperten. 1997; 11: 527–532.

    CAS  Google Scholar 

  82. Perinotto P, Biggi A, Carra N, Orrico A, Valmadre G, Dalľaglio P, Novarinin A, Montanari A. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol 2001; 12: 1706–1712.

    CAS  PubMed  Google Scholar 

  83. Mulkerrin EC, Clark BA, Epstein FH: Increased salt retention and hypertension from non-steroidal agents in the elderly. Q J Med 1997; 90: 411–415.

    CAS  Google Scholar 

  84. Alam S, Purdie DM, Johnson AG. Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension J Hyperten 1999; 17: 1195–1202.

    CAS  Google Scholar 

  85. Brater DC, Anderson S, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandings in men. Kidney Int 1985; 27: 66–73.

    CAS  PubMed  Google Scholar 

  86. Bunning RD, Barth WF. Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 1982; 248: 2864–2867.

    Article  CAS  PubMed  Google Scholar 

  87. Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, Pugliese F, Barsotti P, Pecci G, Taggi F, Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease: evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984; 310: 279–283.

    CAS  PubMed  Google Scholar 

  88. Klassen DK, Stout RL, Spilman PS, Whelton AW. Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. J Clin Pharmacol 1989; 29: 1037–1042.

    CAS  PubMed  Google Scholar 

  89. Mistry CD, Lote CJ, Gokal R, Currie WJ, Vandenberg M, Mallick NP. Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency. Clin Sci 1986; 70: 501–505.

    CAS  PubMed  Google Scholar 

  90. Quintero E, Gines P, Arroya V, Rimola A, Camps J, Gaya J, Guevara A, Rodamilans M, Rodes J. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in patients with cirrhosis and ascites. Nephron 1986; 42: 298–303.

    CAS  PubMed  Google Scholar 

  91. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804–817.

    Article  CAS  PubMed  Google Scholar 

  92. Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulonephropathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol 1990; 30: 468–475.

    CAS  PubMed  Google Scholar 

  93. Rocha JL, Fernandez-Alonso J: Acute interstitial nephritis associated with the seledcitve COX-2 enzyme inhibitor, rofecoxib. Lancet 2001;357:1946–1947.

    Article  CAS  PubMed  Google Scholar 

  94. Henao, J, Hisamuddin J, Nzerue CM, Vasandaui G, Hewan-Lowe K: Celecoxib-induced acute interstitial nephritis. Am J Kid Dis 2002:39:1313–1317.

    PubMed  Google Scholar 

  95. Alper AB, Meleg-Smith S, Krane NK: Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kid Dis 2002;40:1086–1090.

    PubMed  Google Scholar 

  96. Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4: 1–6.

    CAS  PubMed  Google Scholar 

  97. Levin ML. Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs. Sem Nephrol 1988; 8: 55–61.

    CAS  Google Scholar 

  98. Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179–190.

    CAS  PubMed  Google Scholar 

  99. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence for a common mechanism. Br J Clin Pharmacol 1999; 47: 203–210.

    Article  CAS  PubMed  Google Scholar 

  100. Bender WL, Whelton A, Beschorner WE, Darwish MO, Hall-Craggs M, Solez K. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs: immunologic characterization of the inflammatory infiltrate. Am J Med 1984; 76: 1006–1012.

    Article  CAS  PubMed  Google Scholar 

  101. Stachura I, Jayakumar S, Bourke E. T+B lymphocyte subsets in fenoprofen nephropathy. Am J Med 1983; 75: 9–16.

    Article  CAS  PubMed  Google Scholar 

  102. Shibasaki T, Ishimoto F, Sakai O, Joh K, Aizawa S. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol 1991;11:174–180.

    CAS  PubMed  Google Scholar 

  103. Radford MGJr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, McCarthy JT: reversible membranous nephropathy associated with the used of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276: 466–469.

    Article  CAS  PubMed  Google Scholar 

  104. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the used of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 1994; 331: 1675–1679.

    Article  CAS  PubMed  Google Scholar 

  105. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk of chronic renal disease. Ann Intern Med 1991; 115: 165–172.

    CAS  PubMed  Google Scholar 

  106. Field TS, Gurwitz JH, Glynn RJ, Salive ME, Gaziano JM, Taylor JO, Hennekens CH. The renal effects of nonsteroidal anit-inflammatory drugs in older people: findings from the established populations for epidemiologic studies of the elderly. J Am Soc Geriatr Soc 1999; 47: 507–511.

    CAS  Google Scholar 

  107. Sturmer T, Elseviers MM, De Broe ME. Nonsteroidal anti-inflammatory drugs and the kidney. Curr Opin Nephrol Hypert 2001; 10: 161–163.

    CAS  Google Scholar 

  108. Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of non-steroidal antiinflammatory drugs: The importance of half-life and other medications. Am J Med 2001; 111: 521–527.

    CAS  PubMed  Google Scholar 

  109. Calvo-Alen J, De Cos MA, Rodriguez-Valverde V, Escallada R, Florez J, Arias M. Subclinical renal toxicity in rheumatic patients receiving longterm treatment with nonsteroidal anti-inflammatory drugs. J Rheum 1994; 21: 1742–1747.

    CAS  PubMed  Google Scholar 

  110. Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominate analgesic. Am J Kidney Dis 1996; 24: 17–24.

    Google Scholar 

  111. Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981; 24: 1208–1210.

    CAS  PubMed  Google Scholar 

  112. Robertson CE, Ford MJ, Van Somerem V, Dlugolecka M, Prescott LF. Mefenamic acid nephropathy. Lancet 1980; 2: 232–233.

    CAS  PubMed  Google Scholar 

  113. Husserl FE, Lange RK, Kantorw CMJ. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979; 242: 1896–1898.

    Article  CAS  PubMed  Google Scholar 

  114. Atta MG, Whelton A. Acute renal papillary necrosis induced by ibuprofen. Am J Ther 1996; 4: 55–60

    Google Scholar 

  115. Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs 1986; 32(Suppl 4): 109–128.

    PubMed  Google Scholar 

  116. Kirschenbaum MA, White N, Stein JH, Ferris TF. Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Med 1974; 227: 801–805.

    CAS  Google Scholar 

  117. Stein JH, Fadem SZ. The renal circulation. JAMA 1978; 239: 1308–1312.

    Article  CAS  PubMed  Google Scholar 

  118. Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981; 24: 1208–1210.

    CAS  PubMed  Google Scholar 

  119. Lourie SH, Denman SJ, Schroeder ET. Association of renal papillary necrosis and ankylosing spondylitis. Arthritis Rheum 1977; 20: 917–921.

    CAS  PubMed  Google Scholar 

  120. Morales A, Steyn J. Papillary necrosis following phenylbutazone ingestion. Arch Surg 1971; 103: 420–421.

    CAS  PubMed  Google Scholar 

  121. Husserl FE, Lange RK, Kantrow CM Jr. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979; 242: 1896–1898.

    Article  CAS  PubMed  Google Scholar 

  122. Robertson CE, Ford MJ, Van Someren V, Dlugolecka M, Prescott LF. Mefenamic acid nephropathy. Lancet 1980; 2: 232–233.

    CAS  PubMed  Google Scholar 

  123. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyren O. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801–1808.

    Article  CAS  PubMed  Google Scholar 

  124. Weisman JI, Bloom B. Anuria following phenylbutazone therapy. N Engl J Med 1955; 252: 1086–1087.

    CAS  PubMed  Google Scholar 

  125. Lipsett MB, Goldman R. Phenylbutazone toxicity: report of a case of acute renal failure. Ann Intern Med 1954; 41: 1075–1079.

    CAS  PubMed  Google Scholar 

  126. Hart D, Ward M, Lifschitz MD. Suprofen-related nephrotoxicity. A distinct clinical syndrome. Ann Intern Med 1987; 106: 235–238.

    CAS  PubMed  Google Scholar 

  127. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–235.

    CAS  PubMed  Google Scholar 

  128. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. COX-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8: 49–64.

    CAS  PubMed  Google Scholar 

  129. Lipsky PE, Abramson SB, Crofford L, Dubois MD, Simon LS, van de Putte LBA: the classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298–2303.

    CAS  PubMed  Google Scholar 

  130. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–1255.

    Article  CAS  PubMed  Google Scholar 

  131. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, for the VIGOR study group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–1528.

    Article  CAS  PubMed  Google Scholar 

  132. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–1690.

    CAS  PubMed  Google Scholar 

  133. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a new cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized controlled trial. J Clin Pharmacol 2000; 40: 124–132.

    Article  CAS  PubMed  Google Scholar 

  134. Cryer B, Gottesdiener K, Gertz B, Wong P, Dallob A, Feldman M. In vivo effects of rofecoxib, a new cyclooxygenase (COX)-inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane (TXB2) synthesis in healthy humans. Gastroenterology 1999; 116: G0611.

    Google Scholar 

  135. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929–1933.

    Article  CAS  PubMed  Google Scholar 

  136. O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–160.

    CAS  PubMed  Google Scholar 

  137. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76–84.

    CAS  PubMed  Google Scholar 

  138. Swan, SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson P, Schwartz JK, Musliner TA, Gertz BJ, Brater C, Yao SL. Effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1–9.

    CAS  PubMed  Google Scholar 

  139. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85–95.

    CAS  PubMed  Google Scholar 

  140. Whelton A, White WB Bello AE, Puma JA, Fort JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients >or= 65years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959–963.

    Article  CAS  PubMed  Google Scholar 

  141. Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC: Nonnarcotic analgesic use and the risk of hypertension in US women. Hyperten 2002; 40: 604–608.

    CAS  Google Scholar 

  142. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood-pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–838.

    CAS  PubMed  Google Scholar 

  143. Kilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U: Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 2002;42:985–994.

    Google Scholar 

  144. Reitblat T, Zamir D, Estis L, Priluk R, Drogenikov T, Viskoper JR: The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Human Hyperten. 2002;16:431–434.

    CAS  Google Scholar 

  145. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2000.

    Google Scholar 

  146. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

    Google Scholar 

  147. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CS, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-Eur) Trial Investigators. Lancet 1997; 350: 757–764.

    CAS  PubMed  Google Scholar 

  148. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–1975.

    Google Scholar 

  149. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.

    Article  CAS  PubMed  Google Scholar 

  150. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90(Suppl 5A): 42–47.

    Google Scholar 

  151. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35: 937–940.

    CAS  PubMed  Google Scholar 

  152. Wolf G, Porth H, Stahl RAK. Acute renal failure associated with rofecoxib. Ann Intern Med 2000; 133: 394 [letter].

    CAS  PubMed  Google Scholar 

  153. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002;25:537–544.

    Article  CAS  PubMed  Google Scholar 

  154. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM: A comparison of renal-related adverse drug rfeactions between rofecoxib and celecoxib, based on World Health Organization/Uppsala Monitoring Centre safety database. Clin Therap 2001;23:1478–1491.

    CAS  Google Scholar 

  155. Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108–1112.

    Article  CAS  PubMed  Google Scholar 

  156. Page K, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An unrecognized public health problem. Arch Intern Med 2000; 160: 777–784.

    Article  CAS  PubMed  Google Scholar 

  157. Feenstra J, Heerdink ER, Grobbee DE, Stricker BHC: Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam study. Arch Intern Med 2002;162: 265–270.

    Article  CAS  PubMed  Google Scholar 

  158. Graham DY, Agrawal MN, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebocontrolled trial. Lancet 1988; 2: 1277–1280.

    CAS  PubMed  Google Scholar 

  159. Johnston HH, Herzog JP, Lauler DP. Effect of prostaglandin E1 on renal hemodynamics, sodium and water excretion. Am J Physiol 1967; 213: 939–946.

    CAS  PubMed  Google Scholar 

  160. Fülgraff G, Brandenbusch G. Comparison of the effects of prostaglandins A1, E2, and F2a on kidney function in dogs. Pflüger’s Archiv 1974; 349: 9–17.

    Google Scholar 

  161. Chang LCT, Splawinski JA, Oates JA, Nies AS. Enhanced renal prostaglandin production in the dog. Effects on renal function; effects on intrarenal hemodynamics. Circ Res 1975; 36: 197–207.

    Google Scholar 

  162. Strandhoy JW, Ott E, Schneider EG, Willis LR, Beck NP, Davis BB, Knox FG. Effects of prostaglandins E1 and E2 on renal sodium reabsorption and Starling forces. Am J Physiol 1974; 226: 1015–1021.

    CAS  PubMed  Google Scholar 

  163. Paller M. The prostaglandin E1 analog misoprostol reverses acute cyclosporine nephrotoxicity. Transplant Proc 1988; 20(Suppl 3): 634–637.

    CAS  PubMed  Google Scholar 

  164. Weir MR, Klassen DK, Hall PS, Schubert C. Misoprostol minimizes indomethacin-induced renal dysfunction in healthy women: a preliminary report. In: Abstract book 22nd Annual Meeting of the American Society of Nephrology. Washington DC; 1989: 309A.

    Google Scholar 

  165. Antillon M, Cominelli F, Los S, Somberg K, Moran M, Reynolds TB, Zipser RD. Effect of oral prostaglandin in indomethacin induced renal dysfunction on alcoholic cirrhosis: a double-blind randomized study. Gastroenterology 1988; 94: A522.

    Google Scholar 

  166. Boers M, Dijkmans BAC, Breedveld FC, Camps JA, Chang PC, Van Brummelen P, Pauwels EK, Cats A. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. Brit J Rheumatol 1991; 30: 56–59.

    CAS  Google Scholar 

  167. Whelton A, Scott H, Stout RL. Effects of misoprostol on nonsteroidal anti-inflammatory drug induced renal insufficiency in patients with stable chronic renal failure: a double-blind, crossover study. Am J Therap 1995; 2(11): 858–863.

    Google Scholar 

  168. Gurkowski L, MacDougal M, Weigmann T. Effects of misoprostol on contrast-induced renal dysfunction. Am J Therap 1995; 2(11): 837–842.

    Google Scholar 

  169. Russell MW, Miller JD, Taylor DCA, Huse DM: Projected risks and costs of cardiovascular disease due to increased systolic blood pressure associated with use of rofecoxib. Am J Hypert 2001; 14: 195A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universal Clinical Research Center and Johns Hopkins University, Baltimore, Maryland, USA

    Andrew Whelton

  2. German Centre for Research on Ageing, Heidelberg, Germany

    Til Sturmer

  3. Oregon Health Science University, Portland, Oregon, USA

    George A. Porter

Authors
  1. Andrew Whelton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Til Sturmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George A. Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nephrology and Hypertension, University of Antwerp, Belgium

    Marc E. de Broe

  2. Department of Medicine, The Oregon Health Sciences University, Portland, Oregon, USA

    George A. Porter

  3. Northwest Renal Clinic, Legacy Good Samaritan Hospital, Portland, Oregon, USA

    William M. Bennett

  4. Department of Nephrology and Hypertension, University of Antwerp, Belgium

    Gert A. Verpooten

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Whelton, A., Sturmer, T., Porter, G.A. (2003). Non-steroidal anti-inflammatory drugs. In: de Broe, M.E., Porter, G.A., Bennett, W.M., Verpooten, G.A. (eds) Clinical Nephrotoxins. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2586-6_14

Download citation

  • DOI: https://doi.org/10.1007/1-4020-2586-6_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-1277-8

  • Online ISBN: 978-1-4020-2586-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation